Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old

Area of Science:

• Immunology
• Vaccinology
• Pediatric Infectious Diseases

Background:

• Lyme disease is a significant public health concern, particularly in endemic areas.
• Current prevention strategies rely heavily on personal protective measures against tick bites.
• Development of effective vaccines is crucial for controlling Lyme disease transmission.

Purpose of the Study:

• To evaluate the safety and immunogenicity of a recombinant Lyme disease vaccine in children aged 2-5 years.
• To determine the optimal dosage for a pediatric Lyme disease vaccine regimen.
• To assess the duration of protective antibody levels following vaccination.

Main Methods:

• A randomized clinical trial involving children aged 2-5 years.
• Administration of two doses of a recombinant Lyme disease vaccine at 15 and 30 microg dosages.
• Evaluation of vaccine tolerance and adverse events.
• Measurement of antibody titers using ELISA (Enzyme-Linked Immunosorbent Assay) at various time points post-vaccination.

Main Results:

• The recombinant Lyme disease vaccine was well tolerated in children aged 2-5 years across both 15 and 30 microg dose groups.
• Both vaccine doses demonstrated high immunogenicity, with geometric mean titers of 4366 and 9877 ELISA units (EU)/mL one month post-vaccination, respectively.
• A high proportion of subjects achieved antibody levels exceeding 1400 EU/mL, a threshold associated with protective immunity against tick transmission.

Conclusions:

• The recombinant Lyme disease vaccine is safe and highly immunogenic in young children.
• The vaccine elicits antibody levels suggestive of protection against Lyme disease for at least one tick season.
• Further studies are warranted to confirm long-term efficacy and optimal vaccination schedules.